ReviewBest practice & research. Clinical rheumatology2026
Future directions of osteoanabolic therapies in osteoporosis: Integrating current anabolic agents and emerging senescence-targeted strategies.
Review in Best practice & research. Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Osteoporosis therapeutics have advanced from antiresorptive drugs that slow bone loss to osteoanabolic and dual-action agents that can rapidly rebuild skeletal integrity and reduce fracture risk. Yet the current anabolic era leaves important clinical questions unresolved: why responses vary among older adults, why gains are transient, how best to sequence therapy, and how to sustain skeletal resilience in the biologically aged bone microenvironment. Cellular senescence has emerged as a plausible mechanistic bridge linking skeletal aging, chronic inflammation, impaired osteoblastogenesis, increased osteoclastogenesis, marrow adiposity, diabetes-associated fragility, and delayed repair. Preclinical studies show that senescent-cell clearance can prevent or partially reverse age-related bone loss, while early human senolytic data suggest that skeletal response may depend on baseline senescent-cell burden. This review discusses current anabolic therapies, the rationale for senescence-targeted approaches, and future biomarker-informed strategies to integrate anabolic induction, antiresorptive consolidation, and experimental modulation of skeletal aging biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.